Nabriva Therapeutics is in the biotechnology industry and is in the healthcare sector. The company CEO is Theodore R. Schroeder. Nabriva Therapeutics AG is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics.



Previous Intraday Performance:

The NBRV shares had a previous change of 15.64% which opened at 2.43 and closed at 2.81. It moved to an intraday high of 2.88 and a low of 2.43.

SeekingAlpha:  Paratek: Will Nuzyra Succeed?

Historical Performance:

Over the last five trading days, NBRV shares returned 21.65% and in the past 30 trading days it returned 47.12%. Over three months, it changed 36.41%. In one year it has changed -52.05% and within that year its 52-week high was 6.05 and its 52-week low was 1.12. NBRV stock is 150.89% above its 52 Week Low.

Our calculations result in a 200 day moving average of 2.63 and a 50 day moving average of 2.01. Right now, NBRV stock is trading 6.96% above its 200 day moving average.

SeekingAlpha:  Paratek: Will Nuzyra Succeed?

Liquidity:

The company has a market cap of $188.3m with 67.0m shares outstanding and a float of 66.7m shares. Trading volume was 1,705,036 shares and has experienced an average volume of 677,617 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.

Earnings:

The last annual reported EPS for Nabriva Therapeutics was -2.49 which ended on 31st of December 2017. Based on 4 analyst estimates, the consensus EPS for the next quarter is -0.35.

Below was the last reported quarterly earnings per share:
12-31-2018:  -0.41
09-30-2018:  -0.35
06-30-2018:  -0.44
03-31-2018:  -0.36

The next earnings report will be: 03-15-2019

The long-term trend of the EPS is a vital number as it helps understand the future potential of Nabriva Therapeutics; the EPS growth rate, as it is usually called, is typically displayed as a percentage, which at this time is hard to estimate, but revenue growth has been 3.10% over the last twelve months.



Indicators Also to Watch:

Based on the latest filings, there is 58.30% of institutional ownership.

I calculated the beta to be 2.28

Business Wire:  Prana Receives First Orphan Drug Designation from the FDA for the Treatment of Multiple System Atrophy

Fundamental Numbers:

Based on last reported financials, the company’s return on equity is -107.01%, return on assets is -91.92%, price-to-sales is 25.05 and price-to-book is 1.69.

Company Score Card:

Results are out of six:
 5  : Growth Expectations Result
 5  : Financial Safety Result
 0  : Past Performance Result
 1  : Valuation Result
 0  : Dividend Safety Result
 2  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).

LEAVE A REPLY

Please enter your comment!
Please enter your name here